(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 11.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.12%.
Exelixis's revenue in 2026 is $2,375,491,000.On average, 21 Wall Street analysts forecast EXEL's revenue for 2026 to be $662,320,643,705, with the lowest EXEL revenue forecast at $620,847,055,010, and the highest EXEL revenue forecast at $707,061,848,479. On average, 20 Wall Street analysts forecast EXEL's revenue for 2027 to be $746,273,241,427, with the lowest EXEL revenue forecast at $590,935,800,133, and the highest EXEL revenue forecast at $837,515,136,556.
In 2028, EXEL is forecast to generate $837,515,136,556 in revenue, with the lowest revenue forecast at $587,416,828,971 and the highest revenue forecast at $961,181,837,392.